Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
We have recently reported that the administration of AM404, an inhibitor of the endocannabinoid re‐uptake process, which also has affinity for the vanilloid VR1 receptors, is able to reduce hyperkinesia, and causes recovery from neurochemical deficits, in a rat model of Huntington's disease (HD) generated by bilateral intrastriatal injections of 3‐nitropropionic acid (3NP). In the present study, we wanted to explore the mechanism(s) by which AM404 produces its antihyperkinetic effect in 3NP‐lesioned rats by employing several experimental approaches. First, we tried to block the effects of AM404 with selective antagonists for the CB1 or VR1 receptors, i.e. SR141716A and capsazepine, respectively. We found that the reduction caused by AM404 of the increased ambulation exhibited by 3NP‐lesioned rats in the open‐field test was reversed when the animals had been pre‐treated with capsazepine but not with SR141716A, thus suggesting a major role of VR1 receptors in the antihyperkinetic effects of AM404. However, despite the lack of behavioral effects of the CB1 receptor antagonist, the pretreatment with this compound abolished the recovery of neurochemical [γ‐aminobutyric acid (GABA) and dopamine] deficits in the caudate‐ putamen caused by AM404, as also did capsazepine. In a second group of studies, we wanted to explore the potential antihyperkinetic effects of various compounds which, compared to AM404, exhibit more selectivity for either the endovanilloid or the endocannabinoid systems. First, we tested VDM11 or AM374, two selective inhibitors or the endocannabinoid re‐uptake or hydrolysis, respectively. Both compounds were mostly unable to reduce hyperkinesia in 3NP‐lesioned rats, although VDM11 produced a certain motor depression, and AM374 exhibited a trend to stimulate ambulation, in control rats. We also tested the effects of selective direct agonists for VR1 (capsaicin) or CB1 (CP55,940) receptors. Capsaicin exhibited a strong antihyperkinetic activity and, moreover, was able to attenuate the reductions in dopamine and GABA transmission provoked by the 3NP lesion, whereas CP55,940 had also antihyperkinetic activity but was unable to cause recovery of either dopamine or GABA deficits in the basal ganglia. In summary, our data indicate a major role for VR1 receptors, as compared to CB1 receptors, in the antihyperkinetic effects and the recovery of neurochemical deficits caused in 3NP‐lesioned rats by compounds that activate both CB1 and VR1 receptors, either directly or via manipulation of the levels of endogenous agonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide
Zygmunt, P. M., Petersson, J., Andersson, D. A., Chuang, H.-H., Sørgård, M., Di Marzo, V., Julius, D., & Högestätt, E. D. (1999) · Nature · doi:10.1038/22761 · Cited by 2,142
Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system
Tsou, K., Brown, S., Sañudo-Peña, M. C., Mackie, K., & Walker, J. M. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00436-3 · Cited by 1,586 · cited 1×
“As CB1 receptors are located on those neurons that degenerate in HD (Herkenham et al. 1991; Mailleux and Vanderhaeghen 1992; Tsou et al. 1998) and their activation decreases movement (Crawley et al. 1993; Fride and Mechoulam 1993; Wickens and Pertwee 1993; Smith et al. 1994; Romero et al. 1995a,…”
BackgroundMezey, É., Tóth, Z. E., Cortright, D. N., Arzubi, M. K., Krause, J. E., Elde, R., Guo, A., Blumberg, P. M., & Szallasi, A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3655 · Cited by 850 · cited 7×
“VR1 receptors, in turn, were reported to be present also in the basal ganglia (Mezey et al. 2000) and shown to be involved in the production of hypokinesia by capsaicin (Di Marzo et al.”
BackgroundInfluentialThe endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1)
Smart, D., Gunthorpe, M. J., Jerman, J. C., Nasir, S., Gray, J., Muir, A. I., Chambers, J. K., Randall, A. D., & Davis, J. B. (2000) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703050 · Cited by 775
Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid
Brouillet, E., Jenkins, B. G., Hyman, B. T., Ferrante, R. J., Kowall, N. W., Srivastava, R., Roy, D. S., Rosen, B. R., & Beal, M. F. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb05859.x · Cited by 367 · cited 2×
“…by which AM404 produces its antihyperkinetic effects in the rat model of HD generated by bilateral intrastriatal injections of 3NP (Beal et al. 1993; Brouillet et al. 1993; Reynolds et al. 1997), the accuracy of which has been largely discussed in a previous report (Lastres-Becker et al. 2002c).”
BackgroundMethodDe Petrocellis, L., Bisogno, T., Davis, J. B., Pertwee, R. G., & Di Marzo, V. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)02082-2 · Cited by 347
The anandamide transport inhibitor AM404 activates vanilloid receptors
Zygmunt, P. M., Chuang, H.-H., Movahed, P., Julius, D., & Högestätt, E. D. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00207-7 · Cited by 270
Ross, R. A., Gibson, T. M., Brockie, H. C., Leslie, M., Pashmi, G., Craib, S. J., Di Marzo, V., & Pertwee, R. G. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0703850 · Cited by 237
Cited by
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
“Indeed, data from animal models demonstrated that both CB1 agonists and inhibitors of endocannabinoid transport are able to reduce hyperkinesia (Lastres-Becker et al., 2002b, 2003a).”
BackgroundInfluentialCannabinoids and the expanded endocannabinoid system in neurological disorders
Cristino, L., Bisogno, T., & Di Marzo, V. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0284-z · Cited by 970
Ligresti, A., De Petrocellis, L., & Di Marzo, V. (2016) · Physiological Reviews · doi:10.1152/physrev.00002.2016 · Cited by 469
Self-citationEndovanilloids: Putative endogenous ligands of transient receptor potential vanilloid 1 channels
van der Stelt, M., & Di Marzo, V. (2004) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.2004.04081.x · Cited by 389
Self-citationBiochemistry and pharmacology of endovanilloids
Starowicz, K., Nigam, S., & Di Marzo, V. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.01.005 · Cited by 383
Self-citation
Metadata
- Authors
- Lastres‐Becker, I., De Miguel, R., De Petrocellis, L., Makriyannis, A., Di Marzo, V., & Fernández‐Ruiz, J.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2003-02-18
- Volume
- 84
- Issue
- 5
- Pages
- 1097-1109
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1579877956
- Cited by
- 144
- References
- 8
- FWCI
- 7.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease. https://app.cochat.ai/papers/10.1046/j.1471-4159.2003.01595.x
- The paper
- Lastres‐Becker, I., De Miguel, R., De Petrocellis, L., Makriyannis, A., Di Marzo, V., & Fernández‐Ruiz, J. (2003). Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease. Journal of Neurochemistry. https://doi.org/10.1046/j.1471-4159.2003.01595.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.